TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27629859

Group type: EXPERIMENTAL
Intervention: TDF/PI-48w (tenofovir disoproxil fumarate 300 mg/day plus pegylated interferon 180 μg/week for 48 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TDF/PI-16w+TDF-32w (tenofovir disoproxil fumarate plus pegylated interferon for 16 weeks, then tenofovir for 32 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TDF-120w (tenofovir disoproxil fumarate for 120 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PI-48w (pegylated interferon for 48 weeks)
Number of subjects: 0
Study: 24991037

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interval aerobic exercise training
Number of subjects: 60
Study: 22989707

Group type: EXPERIMENTAL
Intervention: Routine oxytocin use
Number of subjects: 252

Group type: COMPARATOR
Intervention: Oxytocin discontinuation (DC)
Number of subjects: 252
Study: 19604092

Group type: EXPERIMENTAL
Intervention: Clozapine or Olanzapine (specific dosage not mentioned)
Number of subjects: 129
Study: 17544778

Group type: COMPARATOR
Intervention: Focal photocoagulation
Number of subjects: 109

Group type: COMPARATOR
Intervention: 20‐mg anterior sub‐Tenon injection of triamcinolone
Number of subjects: 109

Group type: COMPARATOR
Intervention: 20‐mg anterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: 40‐mg posterior sub‐Tenon injection of triamcinolone
Number of subjects: 109

Group type: COMPARATOR
Intervention: 40‐mg posterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Number of subjects: 109
Study: 14968084

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin (Visudyne®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 0
Study: 11403730

Group type: EXPERIMENTAL
Intervention: Nicotine 4-mg gum + cigarette
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nicotine 4-mg gum + unlit cigarette
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo gum + cigarette
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nicotine 4-mg gum
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All treatment groups during exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concomitant gum plus smoking
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 19
Study: 9564062

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 67
Study: 9717054

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study: 2488099

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 0
Study: 402658

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0
Study: 31665277

Group type: EXPERIMENTAL
Intervention: Isolated CABG + ablation
Number of subjects: 7879
Study: 30902081

Group type: EXPERIMENTAL
Intervention: J2SI Phase 2 program (n=90)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard service provision (n=96)
Number of subjects: 186
Study: 28690088

Group type: EXPERIMENTAL
Intervention: Active screening for metabolic control and diabetes-related complications
Number of subjects: 599

Group type: COMPARATOR
Intervention: Routine care with similar education
Number of subjects: 599
Study: 25473041

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 500

Group type: COMPARATOR
Intervention: Exercise Stress Test (EST)
Number of subjects: 500
Study: 23845563

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 11

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21853762

Group type: EXPERIMENTAL
Intervention: Monitored compliance group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unmonitored compliance group
Number of subjects: 20
Study: 19252110

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 5060
Study: 16398726

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilized prophylactic granulocyte transfusions (Cohort G)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (Cohort C)
Number of subjects: 151
Study: 15607394

Group type: EXPERIMENTAL
Intervention: Alcohol septal ablation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Surgical septal myectomy
Number of subjects: 175
Study: 11736861

Group type: EXPERIMENTAL
Intervention: Fluticasone via pMDI
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluticasone via Diskus
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 21
Study: 9415540

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation plus low-dose prednisone (TLI-LDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TLI-LDP
Number of subjects: 0
Study: 8214746

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 40
Study: 3316317

Group type: EXPERIMENTAL
Intervention: 5.0 mg nickel sulfate taken once a week for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5 mg nickel sulfate taken daily
Number of subjects: 24
Study: 30691866

Group type: EXPERIMENTAL
Intervention: Protein-Carbohydrate group (PC) - 30g whey protein immediately after exercise and 30g maltodextrin in the afternoon
Number of subjects: 34

Group type: COMPARATOR
Intervention: Carbohydrate-Protein group (CP) - 30g maltodextrin immediately after exercise and 30g whey protein in the afternoon
Number of subjects: 34
Study: 30021646

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg/100 mL)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl 100 mL)
Number of subjects: 264
Study: 23407278

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) rebounders
Number of subjects: 279
Study: 26270306

Group type: EXPERIMENTAL
Intervention: Lay Health Worker (LHW) intervention with 2 educational sessions on CRC screening
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control group with 2 sessions on healthy eating and physical activity
Number of subjects: 640
Study: 22384925

Group type: EXPERIMENTAL
Intervention: Low temperature quantum molecular resonance (QMR) device
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional high temperature electrocautery
Number of subjects: 33
Study: 20149586

Group type: EXPERIMENTAL
Intervention: Decision support system
Number of subjects: 13

Group type: COMPARATOR
Intervention: Attending clinicians
Number of subjects: 13
Study: 18765433

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg) plus Ezetimibe (10 mg)
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study: 15990426

Group type: EXPERIMENTAL
Intervention: Galantamine prolonged-release capsule (PRC) at doses of 16 or 24 mg/day
Number of subjects: 971

Group type: COMPARATOR
Intervention: Galantamine prolonged-release capsule (PRC)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Galantamine PRC
Number of subjects: 971
Study: 12723400

Group type: EXPERIMENTAL
Intervention: 100 mg per day of itraconazole (ITCZ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg per day of itraconazole (ITCZ)
Number of subjects: 12
Study: 10506042

Group type: EXPERIMENTAL
Intervention: Injection with 10 mg lignocaine and 40 mg methylprednisolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 mg lignocaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-responders in control group receiving 40 mg methylprednisolone
Number of subjects: 60
Study: 9005799

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 5 days (IV for first 2 days, then oral for next 3 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 3 days (oral) + intravenous infusion of 200 mg twice a day for 3 days (for medium disease)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg twice a day for 5 days (for chronic carriers)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ofloxacin (dosage not specified)
Number of subjects: 31
Study: 1848715

Group type: EXPERIMENTAL
Intervention: Ethiodized poppy‐seed oil
Number of subjects: 417

Group type: COMPARATOR
Intervention: Water-soluble media (diatrizoate meglumine, ioxaglate, iohexol)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Water-soluble media
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: All contrast media
Number of subjects: 417
Study: 6751704

Group type: EXPERIMENTAL
Intervention: Budesonide ointment (treated under occlusive dressings for 1 week)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Budesonide ointment (treated for 2 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (treated under occlusive dressings for 1 week)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (treated for 2 weeks)
Number of subjects: 119
Study: 31395484

Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 90 minutes (short CRI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 180 minutes (long CRI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfaxalone bolus (3 mg kg‐1) followed by CRI
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI (short and long)
Number of subjects: 6
Study: 27682229

Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving treatment (IPST)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 171
Study: 26007680

Group type: EXPERIMENTAL
Intervention: Systemic administration of antibiotics (Amoxicillin + Metronidazole)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 36
Study: 24213602

Group type: EXPERIMENTAL
Intervention: Elevated circulating estradiol (Q5 vs Q1)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Elevated ratio of the 2-hydroxylation pathway (Q5 vs Q1)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Elevated ratio of the 4-hydroxylation pathway (Q5 vs Q1)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Higher ratio of the 2/16-hydroxylation pathways (Q5 vs Q1)
Number of subjects: 496
Study: 21123447

Group type: EXPERIMENTAL
Intervention: Low-dose folic acid (0.4 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ovarian stimulation without folic acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional ovarian stimulation
Number of subjects: 50
Study: 20630505

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy in endometrioma group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy in nonendometrioma group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Basal FSH levels (both groups)
Number of subjects: 50
Study: 17906344

Group type: EXPERIMENTAL
Intervention: Postconditioning (3 cycles of 30-second angioplasty balloon deflation and 30-second inflation during the first 3 minutes of reperfusion)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no intervention applied in the first 3 minutes of reperfusion)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 15899653

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins C and E, beta-carotene, and selenium) along with methimazole therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Methimazole therapy alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 55
Study: 12237730

Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestorage leukoreduction
Number of subjects: 0
Study: 9523214

Group type: EXPERIMENTAL
Intervention: FRAXA mutation screening
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: FRAXE mutation screening
Number of subjects: 433
Study: 7640130

Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 80
Study: 2677301

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.i.d.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 318715

Group type: EXPERIMENTAL
Intervention: Vitamin C (dosages dependent on body weight)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (untreated co-twins)
Number of subjects: 44
Study: 31756291

Group type: EXPERIMENTAL
Intervention: cSAM phenotype at index admission (kwashiorkor)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: cSAM phenotype at index admission
Number of subjects: 1704
Study: 31567791

Group type: EXPERIMENTAL
Intervention: Front Squat (FS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sumo Deadlift (SD)
Number of subjects: 24
Study: 27022012

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis + Stent Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis Alone Group
Number of subjects: 0
Study: 26159179

Group type: EXPERIMENTAL
Intervention: Immediate access to a fully automated online assessment and intervention with personalized feedback
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Delayed access to a fully automated online assessment and intervention with personalized feedback
Number of subjects: 1605
Study: 23727740

Group type: EXPERIMENTAL
Intervention: 5000ppm sodium fluoride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GC MI paste plus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinpro tooth crème
Number of subjects: 30
Study: 20737210

Group type: COMPARATOR
Intervention: Oral 5-aminosalicylic acid (5-ASA) alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral 5-ASA plus oral Lactobacillus casei DG
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral 5-ASA and rectal Lactobacillus casei DG
Number of subjects: 26
Study: 19283953

Group type: EXPERIMENTAL
Intervention: HCV-positive individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV-positive men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criminal risk factors
Number of subjects: 0
Study: 16634751

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg day(-1) for 1 week
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1, then 75 mg day(-1)) for 1 week
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Aspirin and Clopidogrel
Number of subjects: 96
Study: 14523094

Group type: EXPERIMENTAL
Intervention: Input from temporal retina in albinism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal routing of temporal fibers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal input to visual cortex in human albinism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormal input in striate and extrastriate areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topographic mapping in human albinism
Number of subjects: 0
Study: 11009291

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8629306

Group type: COMPARATOR
Intervention: Triple drug therapy with a 10-day course of OKT3 (group 2, n = 44)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Triple drug therapy with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n = 43)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n = 42)
Number of subjects: 129

Group type: COMPARATOR
Intervention: OKT3 therapy (group 2)
Number of subjects: 129

Group type: COMPARATOR
Intervention: LO-Tact-1 therapy (group 3)
Number of subjects: 129
Study: 1424170

Group type: EXPERIMENTAL
Intervention: Parlodel LAR 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Parlodel LAR 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Parlodel LAR 100 mg
Number of subjects: 21
Study: 2413294

Group type: EXPERIMENTAL
Intervention: Captopril (2 mg . kg‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitroprusside alone (Control)
Number of subjects: 14
Study: 31895254

Group type: EXPERIMENTAL
Intervention: Absorbable suture lifting
Number of subjects: 12
Study: 29307093

Group type: EXPERIMENTAL
Intervention: Stopping TNF inhibitors (TNFi) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continuing TNF inhibitors (TNFi) therapy
Number of subjects: 35
Study: 26796966

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27129011

Group type: EXPERIMENTAL
Intervention: Topiramate 75 mg every 12 hours and Diltiazem 240 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg every 12 hours and Hydrochlorothiazide 25 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg every 12 hours and Propranolol 40-80 mg every 12 hours
Number of subjects: 0
Study: 21969362

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study: 20334647

Group type: EXPERIMENTAL
Intervention: Inhaled Insulin Treatment Questionnaire (IITQ)
Number of subjects: 1076
Study: 19281060

Group type: EXPERIMENTAL
Intervention: Passive sensory stimulation through tactile coactivation applied to the fingertips for 3 hours.
Number of subjects: 0
Study: 15449184

Group type: EXPERIMENTAL
Intervention: 188Re-HEDP (3194+/‐387 MBq)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP (2940+/‐545 MBq)
Number of subjects: 46
Study: 15201490

Group type: EXPERIMENTAL
Intervention: Patient EQ
Number of subjects: 1

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 1
Study: 11523081

Group type: EXPERIMENTAL
Intervention: Proposed method for analysis of repeated binary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed method for stratified analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pattern mixture model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of proposed method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal risk ratio estimation
Number of subjects: 0
Study: 9263086

Group type: EXPERIMENTAL
Intervention: 2 g of cefamandole at induction of anesthesia (group 1, n = 24)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 2 g of cefamandole at the beginning of anesthesia followed by an additional dose (2 g) immediately after onset of cardiopulmonary bypass (CPB) (group 2, n = 22)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 4 g of cefamandole just at the initiation of anesthesia (group 3, n = 23)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 69
Study: 7508065

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril 12.5 mg three times daily
Number of subjects: 12
Study: 3533236

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.5 mg (approximately 0.007 mg X kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pancuronium 1.0 mg (approximately 0.015 mg X kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.05 mg X kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.1 mg X kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 29575929

Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Number of subjects: 74

Group type: COMPARATOR
Intervention: Matopat Classic adhesive tape (placebo)
Number of subjects: 74
Study: 26763075

Group type: EXPERIMENTAL
Intervention: Sanguinarine (SA) at 10 mg kg(‐1) BW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sanguinarine (SA) at 0, 5, 10 and 20 mg kg(‐1) BW
Number of subjects: 0
Study: 25515398

Group type: EXPERIMENTAL
Intervention: Fructose (50 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sucrose (50 g)
Number of subjects: 14
Study: 22139591

Group type: EXPERIMENTAL
Intervention: LTG XR 300 mg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: LTG XR 250 mg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Historical control (aggregated pseudoplacebo data from 8 trials)
Number of subjects: 226
Study: 20459697

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18639417

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Coumarin
Number of subjects: 165
Study: 16146552

Group type: EXPERIMENTAL
Intervention: Simvastatin 5-10 mg/d for 4 years
Number of subjects: 14
Study: 12966256

Group type: EXPERIMENTAL
Intervention: Neuropathic Pain Questionnaire (NPQ)
Number of subjects: 528
Study: 10815342

Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme (intensive care and post-assistance programme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme (intensive care only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-assistance programme (nine-months with 36 sessions of psychoanalytic group therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilisation of the health care system
Number of subjects: 0
Study: 8829887

Group type: EXPERIMENTAL
Intervention: Core cooling via intravenous infusion of cold saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin-surface cooling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shivering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermal stimuli resulting in core hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin-surface cooling without core hypothermia
Number of subjects: 0
Study: 1622904

Group type: EXPERIMENTAL
Intervention: Silc-cup
Number of subjects: 199

Group type: COMPARATOR
Intervention: Metal cup
Number of subjects: 199
Study: 6531663

Group type: EXPERIMENTAL
Intervention: Beta-blockade (propranolol, 100 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No beta-blockade (control)
Number of subjects: 6